DaVita (DVA) — Customer relationships, contractual posture and investor implications

DaVita operates and monetizes a national kidney-care platform by selling recurring dialysis and related laboratory services to patients and health plans, and by contracting with hospitals and government agencies on a per‑treatment fee basis. Revenue is driven by per‑treatment reimbursements and management fees, with heavy dependence on government payors and U.S. outpatient volume, creating a revenue base that is predictable but exposed to reimbursement policy and payor concentration. Learn more about how this intelligence is assembled at https://nullexposure.com/.

One-line relationship snapshot investors need first

Berkshire Hathaway — referenced as a counterparty in share repurchases executed under a public repurchase agreement; management noted recent repurchases were partially made from Berkshire to keep its ownership at or below 45%. (Q4 2025 earnings call, discussed March 2026.)

All reported relationships, concisely explained

Berkshire Hathaway — Management disclosed that a portion of recent share repurchases were completed under the company’s publicly filed repurchase agreement with Berkshire Hathaway, and that the mechanics of that formula keep Berkshire’s stake at or below 45%. This is a shareholder‑level counterparty arrangement disclosed on the Q4 2025 earnings call. (DaVita Q4 2025 earnings call transcript, first reported March 8, 2026.)

What the contractual evidence and constraints reveal about how DaVita operates

The filing excerpts and related constraints provide a clear picture of DaVita’s commercial structure. Presenting these as company‑level signals shows both strengths and concentrated risks.

Usage‑based, per‑treatment contracting with hospitals: DaVita routinely negotiates per‑treatment fees for hospital inpatient dialysis, indicating a variable revenue model tied directly to treatment volumes rather than fixed‑price long‑term bundles. This is stated in its December 31, 2025 disclosures.
Government payor concentration is a defining feature: Government programs (Medicare/Medicaid and related) account for the majority of U.S. dialysis revenues — company disclosures show approximately 68% of revenues from government‑based programs and U.S. dialysis representing roughly 86% of consolidated revenue, underscoring material dependence on public reimbursement rates. (Company FY2025 disclosures, Dec 31, 2025.)
Large individual patient base underpins recurring cash flow: DaVita served roughly 200,500 patients as of year‑end 2025, confirming scale and a recurring revenue profile driven by patient treatment cycles. (FY2025 disclosures.)
Geographic footprint is overwhelmingly U.S. but with global ambitions: The core operations are U.S. outpatient care (2,657 centers across 46 states and DC), while disclosures also describe strategic global positioning for growth. (FY2025 disclosures.)
Contract maturity and termination posture varies by counterparty: The company has long‑running operational engagements, but some government contracts — for example, the Veterans Administration National Dialysis Service Contract — include short‑notice termination rights, signaling pockets of contractual fragility in critical government relationships. (FY2025 filing language referencing VA NDSC.)
Commercial role is primarily provider/seller: DaVita’s revenue flow is principally as a service provider (seller of dialysis services), collecting payments from government and commercial health plans. The company also acts as a buyer in limited contexts (for example, under the VA contract structure) as disclosed in filings. (FY2025 filings.)

These signals combine into a consistent operating model: highly recurring, volume‑based service revenue concentrated in U.S. government payors, with contract terms that can be usage‑based and, in certain government arrangements, short‑term termination risk.

Mid‑analysis: what investors should focus on now

Investors evaluating counterparty risk and customer dynamics should prioritize the following:

Reimbursement and policy risk — with >60% government payor exposure, changes in Medicare/Medicaid or Medicare Advantage policy will have direct earnings leverage.
Volume sensitivity — per‑treatment contracting means near‑term revenue tracks treatment counts; demographic or referral shifts will translate quickly to reported revenue.
Contract concentration and counterparty criticality — the U.S. dialysis business is critical to consolidated results (≈86%), so operational disruptions in this segment propagate across the company.
Contract enforceability and termination provisions — specific government contracts, such as the VA NDSC, include termination without cause rights, which increases short‑notice operational risk on certain bookings. (See company disclosures as of Dec 31, 2025.)

For a deeper, structured look at counterparties and contractual features, visit https://nullexposure.com/ to see how these relationship signals map to revenue and risk exposures.

Operational implications and runway for margins

DaVita’s margins depend on negotiating favorable per‑treatment rates and keeping utilization stable. Operating margin resilience depends on scale, reimbursement discipline, and the company’s ability to manage clinical costs. The company’s reported operating margin (around mid‑teens on a trailing basis) and EBITDA show capacity to fund buybacks, but governance interactions (such as the repurchase arrangement with Berkshire Hathaway) and patient‑level cost pressures are principal drivers of capital allocation decisions going forward.

Why the Berkshire Hathaway mention matters to investors

The Berkshire reference in the Q4 2025 earnings call is not a customer relationship; it is a shareholder/capital markets arrangement. Management’s disclosure that repurchases were made “pursuant to our publicly filed repurchase agreement” with Berkshire, with mechanics that hold Berkshire’s stake at or below 45%, is a governance and capital‑structure signal that affects minority liquidity, control dynamics, and the mechanics of future buybacks. (Q4 2025 earnings call, March 2026.)

Final verdict and actionables

Key takeaways: DaVita’s business model is volume‑driven, government‑concentrated and usage‑contracted, producing predictable recurring revenue but concentrated policy and counterparty risk. Government contracts can include short‑notice termination rights (notably the VA NDSC), and the company’s governance is influenced by large shareholders as reflected in repurchase arrangements.
Investor actions: Monitor reimbursement rulemaking, outpatient utilization trends, and filings around major government contracts and shareholder agreements. For a concise map of these customer and contract signals and how they affect revenue concentration, explore https://nullexposure.com/.

Bold, clear signals like payor concentration, per‑treatment contracting, and government contract termination language define DaVita’s risk‑return profile. Investors and operators evaluating DVA should weight contractual exposure to public payors and operational leverage to volume when sizing risk and forecasting earnings.

DVA customer relationships